Terns Pharmaceuticals
A clinical-stage biopharma company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH.
The company was founded in 2017 via a $30 million series A funding round from Lilly Asia Ventures, and took on three assets in non-alcoholic steatohepatitis (NASH) programs from Eli Lilly in April 2018.
Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program.
Latest Terns Pharmaceuticals News & Features
13 November 2023
5 August 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze